OBI Pharma’s Obrion® ADC Technology Platform Wins Product Innovation of the Year at the 2026 Taiwan BIO Awards

OBI Holds 2026 Annual Shareholders’ Meeting
Capturing Global Opportunities in Next-Generation ADCs with Its Proprietary Obrion® Platform to Advance Bispecific Dual-Payload ADCs and International Licensing Strategy

OBI Presents Three Featured Talks at the 2026 World ADC Summit South Korea
Highlighting GlycOBI® and Dual-Payload ADC Technologies

The Company’s Board of Directors resolved to issue 2026 employee stock options and the subscription rules

The Company’s BOD resolved to forfeit the subscription of OBIGEN Pharma’s cash capital increase and distribute the rights to its shareholders

Announcement of the Company’s new appointment of financial and corporate governance officer

2025 Annual Report

Learn how we created value in 2025 and worked to pursue our purpose of enabling a healthier world.

Governance

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations